Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of Super-enhancer-associated Cancer Genes Provides Novel Therapeutic Targets in Adult T-cell Leukemia/Lymphoma

ABSTRACT: Identification of Super-enhancer-associated Cancer Genes Provides Novel Therapeutic Targets in Adult T-cell Leukemia/Lymphoma

PROVIDER: PRJNA339120 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR4035090_1.fastq.gz	Fastqsanger.gz
	SRR4035090_2.fastq.gz	Fastqsanger.gz
	SRR4035100_1.fastq.gz	Fastqsanger.gz
	SRR4035100_2.fastq.gz	Fastqsanger.gz
	SRR4035110.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 46

Similar Datasets

Super-enhancer-associated oncogenes as novel therapeutic targets in osteosarcoma

Project description:Super-enhancer-associated oncogenes as novel therapeutic targets in osteosarcoma

| PRJNA555840 | ENA

Super-enhancer-associated oncogenes as novel therapeutic targets in osteosarcoma (ChIP-seq)

Project description:Super-enhancer-associated oncogenes as novel therapeutic targets in osteosarcoma (ChIP-seq)

| PRJNA555843 | ENA

Super-enhancer-associated oncogenes as novel therapeutic targets in osteosarcoma (ChIP-seq)

Project description:Despite the development of diagnostic and advanced treatment strategies, the prognosis of patients with osteosarcoma remains poor. A limited understanding of the pathogenesis of osteosarcomas has impeded any improvement in patient outcomes over the past 4 decades. It is thus urgent to identify novel effective targets and treatment regimens for osteosarcoma patients. In this study we delineated the super-enhancer landscape in osteosarcoma cells on the basis of H3K27ac signal intensity by ChIP-Seq and found that super-enhancer-associated genes contribute to the malignant potential of osteosarcoma. THZ2, a novel small molecular inhibitor, shows a powerful anti-osteosarcoma ability through suppress super-enhancer-associated genes selectively. Utilizing the characteristics of super-enhancers in cancer cells, we identified 5 critical super-enhancer-associated oncogenes. With the comparative and retrospective analysis in large numbers of human specimens from patients, these 5 oncogenes were observed closely related with patient prognosis. Our findings determined that targeting super-enhancer-associated oncogenes with transcriptional inhibitor, THZ2, was a promising therapeutic strategy in osteosarcoma, and provided novel candidate targets for patients with osteosarcoma.

2019-12-27 | GSE134604 | GEO

Adult High Grade B-cell Lymphoma with Burkitt Lymphoma Signature: Genomic features and Potential Therapeutic Targets

Project description:Adult High Grade B-cell Lymphoma with Burkitt Lymphoma Signature: Genomic features and Potential Therapeutic Targets

| PRJNA707396 | ENA

Discovery and Characterization of Super-Enhancer Associated Dependencies in Diffuse Large B-Cell Lymphoma

Project description:Diffuse Large B-Cell Lymphoma (DLBCL) is a biologically heterogeneous and clinically aggressive disease. Here, we explore the role of BET bromodomain proteins in DLBCL, using integrative chemical genetics and functional epigenomics. We observe highly asymmetric loading of BRD4 at enhancers, with approximately 33% of all BRD4 localizing to enhancers at 1.6% of occupied genes. These super-enhancers prove particularly sensitive to bromodomain inhibition, explaining the selective effect of BET inhibitors on oncogenic and lineage-specific transcriptional circuits. Functional study of genes marked by super-enhancers identifies DLBCLs dependent on OCA-B and suggests a strategy for discovering unrecognized cancer dependencies. Translational studies performed on a comprehensive panel of DLBCLs establish a therapeutic rationale for evaluating BET inhibitors in this disease. ChIP-Seq for various transcription factors and histone modifications in diffuse large B-cell lymphoma cells

2013-12-10 | E-GEOD-46663 | biostudies-arrayexpress

Super-enhancer-associated oncogenes as novel therapeutic targets in osteosarcoma (Microarray gene expression data)

Project description:Super-enhancer-associated oncogenes as novel therapeutic targets in osteosarcoma (Microarray gene expression data)

| PRJNA555842 | ENA

Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia

Project description:Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia

| PRJNA642135 | ENA

RUNX1 expression is regulated by a super-enhancer and is a therapeutic target in adult T-cell leukemia/lymphoma

Project description:Super-enhancers (SEs)—genomic enhancer regions with dense accumulation of mediator complexes—play an important role in regulating tumor-specific gene expression and are potential therapeutic targets for neoplastic diseases. Bromodomain-containing protein 4 (BRD4) is a component of the protein complexes that bind to the SE region. JQ1, one of the known BRD4 inhibitors, exerts antitumor effects by suppressing SE-mediated regulation of gene expression. Adult T-cell leukemia/lymphoma (ATL) is highly resistant to available treatments, and its prognosis is extremely poor. As JQ1 has potential as a therapeutic agent for various malignancies, we investigated the anti-ATL effects of JQ1. JQ1 induced apoptosis and inhibited ATL cell proliferation. JQ1 suppressed the expression of RUNX1 through the disruption of SE-mediated gene regulation, indicating that RUNX1 could be a novel therapeutic target molecule. AI-10-104 and Ro5-3335 are RUNX1 inhibitors developed for hematologic malignancies such as acute myeloid leukemia (AML) and lymphoblastic leukemia (ALs). We demonstrated that these two agents reduced cell proliferation in ATL cell lines and patient samples at effective concentrations in ALs with RUNX1 mutations. Simultaneously, AI-10-104 suppressed MYC proto-oncogene (c-MYC) expression. RUNX1 is a potential therapeutic target for ATL that promotes c-MYC expression. For the first time, we showed that RUNX1 expression is regulated via SEs in ATL, a hematologic malignancy of peripheral mature T cells. This study indicates that RUNX1 may be a novel therapeutic target for ATL.

2025-01-13 | GSE253457 | GEO

Functional Proteogenomics Reveals Biomarkers and Therapeutic Targets in Lymphomas

Project description:The proteomic and posttranslational modification signatures of most cancers are unknown. N-linked glycosylation is a post-translational modification that targets proteins for membrane expression or secretion making this class of proteins attractive cancer biomarkers and therapeutic targets. Using an unbiased mass spectrometry (MS)-based approach we generated a compendium of 1,155 N-linked glycoproteins (2,160 N-glycosites) from 44 human primary lymphomas and malignant lymphoma cell lines. Hierarchical clustering highlighted distinct subtype signatures which included several novel subtype-specific biomarkers. Orthogonal immunologic studies in 671 primary lymphoma tissue biopsies, 36 lymphoma-derived cell lines or 8 patient-derived circulating tumor cell samples corroborated MS-based glycoproteomic data and authenticated selected proteins as tissue biomarkers. Functional targeting using a toxin-conjugated ligand in vitro and RNAi-mediated silencing targeting subtype-specific glycoproteins abrogated lymphoma growth in vivo. Our results demonstrate the utility of global N-glycoproteomics discovery of cancer biomarkers and targets for precision therapeutics.

2017-06-19 | PXD003469 | Pride

Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia (4C-Seq)

Project description:Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia (4C-Seq)

| PRJNA642240 | ENA